Skip Navigation


NDT Advance Access originally published online on May 10, 2005
Nephrology Dialysis Transplantation 2005 20(7):1516-1517; doi:10.1093/ndt/gfh902
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/7/1516    most recent
gfh902v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Decupere, M.
Right arrow Articles by Claes, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decupere, M.
Right arrow Articles by Claes, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Letter

Artifactual hypocalcaemia after intravenous administration of gadodiamide (Omniscan®)

The first 10% of the full text of this article appears below.

Sir,

It has been documented that certain gadolinium-based magnetic resonance contrast agents injected for enhancement of magnetic resonance imaging (MRI) or for angiography in selected patients, i.e. gadodiamide (Omniscan®) and gadoversetamide (Optimark®), can cause spurious hypocalcaemia, due to interference with colorimetric assays in a dose-dependent way [1–4]. Three other agents approved for clinical use, gadopentetate . . . [Full Text of this Article]

Marc Decupere, Vanessa Ooms, Raymond Oyen, Dirk R. J. Kuypers and Kathleen Claes

Department of Nephrology and Renal Transplantation University Hospitals Leuven Belgium Email: Kathleen.Claes@uz.kuleuven.ac.be


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?